EVOLUTION-HF: Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom
Study Details
Study Description
Brief Summary
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). On May 5, 2020, the US Food and Drug Administration (FDA) announced the approval of dapagliflozin for heart failure with reduced ejection fraction (HFrEF), regardless of whether the patient has diabetes. Subsequently, there have been additional approvals for this indication by regulatory authorities across the globe." Real-world observational data are necessary to describe dapagliflozin use in real-world settings with detailed clinical data on heart failure symptoms, outcomes, and HRQoL.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Time to dapagliflozin treatment discontinuation [Baseline to 12 months]
Time from dapagliflozin treatment initiation until the time at which participants stop taking the medication for any reason.
- Number of reasons for dapagliflozin treatment discontinuation [Baseline to 12 months]
Number of reason for dapagliflozin treatment discontinuation as noted by a health care professional will extracted and described as the number and proportion of participants who have discontinued dapagliflozin according to each reasons presented.
- Proportion of reasons for dapagliflozin treatment discontinuation [Baseline to 12 months]
Proportion of reasons for dapagliflozin treatment discontinuation as noted by a health care professional will extracted and described as the number and proportion of participants who have discontinued dapagliflozin according to each reasons presented.
- Number of dapagliflozin treatment changes [Baseline to 12 months]
The number of participants who switch to another HF medication other than dapagliflozin.
- Percentage of dapagliflozin treatment changes [Baseline to 12 months]
The percentage of participants who switch to another HF medication other than dapagliflozin.
- Number of dapagliflozin treatment discontinuation [Baseline to 12 months]
The number of participants who discontinued treatment with dapagliflozin.
- Percentage of dapagliflozin treatment discontinuation [Baseline to 12 months]
The percentage of participants who discontinued treatment with dapagliflozin.
- Time to other heart failure treatment discontinuation [Baseline to 12 months]
Time from initiation of heart failure medication other than dapagliflozin until the time at which participants discontinued treatment with that medication.
- Number of other heart failure treatment initiation [Baseline to 12 months]
The number of participants who initiate new heart failure medication other than dapagliflozin.
- Percentage of other heart failure treatment initiation [Baseline to 12 months]
The percentage of participants who initiate new heart failure medication other than dapagliflozin.
- Number of other heart failure treatment dosage changes [Baseline to 12 months]
The number of participants with dosage changes for heart failure medication other than dapagliflozin.
- Percentage of other heart failure treatment dosage changes [Baseline to 12 months]
The percentage of participants with dosage changes for heart failure medication other than dapagliflozin.
- Number of other heart failure treatment discontinuation [Baseline to 12 months]
The number of participants who discontinue treatment with heart failure medication other than dapagliflozin.
- Percentage of other heart failure treatment discontinuation [Baseline to 12 months]
The percentage of participants who discontinue treatment with heart failure medication other than dapagliflozin.
- Time to glucose lowering medication discontinuation [Baseline to 12 months]
Time from initiation of glucose lowering medication other than dapagliflozin until the time at which participants discontinued treatment with that medication.
- Number of glucose lowering medication initiation [Baseline to 12 months]
The number of participants who initiate new glucose lowering medication other than dapagliflozin.
- Percentage of glucose lowering medication initiation [Baseline to 12 months]
The percentage of participants who initiate new glucose lowering medication other than dapagliflozin.
- Number of glucose lowering medication dosage changes [Baseline to 12 months]
The number of participants with dosage changes for glucose lowering medication other than dapagliflozin.
- Percentage of glucose lowering medication dosage changes [Baseline to 12 months]
The percentage of participants with dosage changes for glucose lowering medication other than dapagliflozin.
- Number of glucose lowering medication discontinuation [Baseline to 12 months]
The number of participants who discontinue treatment with glucose lowering medication other than dapagliflozin.
- Percentage of glucose lowering medication discontinuation [Baseline to 12 months]
The percentage of participants who discontinue treatment with glucose lowering medication other than dapagliflozin.
Secondary Outcome Measures
- Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score [Measured at 3, 6, 9 and 12 months]
The KCCQ is a 23-item questionnaire that quantifies physical limitations, self-efficacy, social interference and quality of life. Summary scores will be examined at each assessment point during follow-up. For each of the assessment periods, descriptive statistics for the observed value, change from baseline and the 95% two-sided confidence interval for the mean change will be presented. The proportions of participants with overall health status classified as poor, fair, good, and excellent will be examined at each assessment point. Additionally, the proportions of participants who experience clinically meaningful changes in overall health status: improvement (≥5 point increase), deterioration (≥5 point decrease), and stable (<5 point increase or decrease) will be examined at each assessment point.
- Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire [Measured at 3, 6, 9 and 12 months]
The MARS-5 is five-item self-report adherence scale which assesses both intentional and non-intentional non-adherence. Respondents rate the frequency with which the five different medication-taking behaviours occur, scoring each item on a 1-5-point scale with higher scores indicating higher reported adherence. The MARS-5 has been shown to be reliable and valid across a variety of health conditions, including cardiovascular and pulmonary diseases.
- Absolute change from baseline in Work Productivity and Activity Impairment (WPAI) score [Measured at 3, 6, 9 and 12 months]
The WPAI is a validated instrument to measure impairments in paid and unpaid work and activities. It measures absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness) as well as the impairments in unpaid activity because of health problems during the past seven days. It has been validated to quantify work impairments for numerous diseases such as asthma, psoriasis, irritable bowel syndrome, and Crohn's disease, but has not yet been validated for use in heart failure participants. Scores will be derived from the overall work impairment at each timepoint and then changes of from baseline will be reported.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years as of study index date; the study index date is date of initiation of treatment with dapagliflozin
-
Patient received/receiving treatment with dapagliflozin for HFrEF (EF ≤40%) in accordance with the local dapagliflozin product label
-
Signed and dated informed consent prior to enrolment in the study
Exclusion Criteria:
-
Patient is enrolled less than 14 days or more than 60 days following initiation of dapagliflozin
-
Prior treatment with dapagliflozin or other SGLT2i treatment
-
Initiation of dapagliflozin outside of local HF label
-
Diagnosis of Type 1 diabetes prior to enrolment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Research Site | Reading | Berkshire | United Kingdom | RG1 5AN |
| 2 | Research Site | Truro | Cornwall | United Kingdom | TR1 3LJ |
| 3 | Research Site | Portadown | County Armagh | United Kingdom | BT63 5QQ |
| 4 | Research Site | Barnstaple | Devon | United Kingdom | EX31 4JB |
| 5 | Research Site | Westcliff on Sea | Essex | United Kingdom | SS0 0RY |
| 6 | Research Site | Port Talbot | Glamorgan | United Kingdom | SA12 7BR |
| 7 | Research Site | London | Greater London | United Kingdom | SE5 9RS |
| 8 | Research Site | Stoke-on-Trent | Staffordshire | United Kingdom | AT4 6QG |
| 9 | Research Site | Brighton | Sussex | United Kingdom | BN2 5BE |
| 10 | Research Site | Coventry | Warwickshire | United Kingdom | CV2 2DX |
Sponsors and Collaborators
- AstraZeneca
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D169CR00001